Results 61 to 70 of about 29,283 (270)

Outcomes with liquid biopsy to determine the EGFR mutation status in poor performance status, biopsy-ineligible, advanced NSCLC patients

Cancer Research, Statistics, and Treatment, 2019
Background: Outcomes based on liquid biopsy in poor performance, older, biopsy-ineligible advanced non-small cell lung cancer (NSCLC) patients are unknown.
Avinash Pandey, Sarjana Dutt, Anjana Singh, Amit Kumar, Shivkant Singh   +4 more
doaj   +1 more source

A Panel of Circulating Exosomal sncRNAs Associated With Lung Cancer Risk up to 10 Years in Advance

Advanced Science, EarlyView.
Lung cancer is often diagnosed too late, and current screening overlooks many people at risk. In a long‐term study of smokers, a panel of small non‐coding RNAs carried in blood exosomes signals elevated lung cancer risk up to ten years before diagnosis, pointing toward a blood‐based tool for earlier risk detection.
Zhuokun Feng, Masaki Nasu, Ayman Abdul‐Ghani, Yu Chen, Shaoqiu Chen, Isam Mohd Ibrahim, Hanqiu Zhang, Lauren Higa, Zitong Gao, Hua Yang, Raphael Bueno, Loïc Le Marchand, Youping Deng   +12 more
wiley   +1 more source

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis

Frontiers in Oncology, 2022
Cancer cells release nucleic acids, freely or associated with other structures such as vesicles into body fluids, including blood. Among these nucleic acids, circulating tumor DNA (ctDNA) has emerged as a minimally invasive biomarker for tumor molecular ...
Estela Sánchez-Herrero, Estela Sánchez-Herrero, Roberto Serna-Blasco, Lucia Robado de Lope, Víctor González-Rumayor, Atocha Romero, Atocha Romero, Mariano Provencio, Mariano Provencio   +8 more
doaj   +1 more source

An Aggregation‐Induced Polymerization Poly(Disulfide)‐Drug Nanoplatform for Autoimmune Uveitis Therapy via Inhibiting the cGAS‐STING Pathway

Advanced Science, EarlyView.
A cationic poly(disulfide)‐drug nanoplatform (LA/DexP) was developed to treat experimental autoimmune uveitis (EAU). With potent blood‐retinal barrier penetrability, LA/DexP releases DSP in response to high ROS and scavenges cfDNA to inhibit the cGAS‐STING signaling pathway.
Yuelan Wu, Wenbo Geng, Qinjin Dai, Wanyun Zhang, Yuxian Lai, Pei Zhang, Chunjiang Zhou, Yinuo Wang, Qingfeng Cao, Xiang Luo, Yujie Lai, Changwei Huang, Peizeng Yang   +12 more
wiley   +1 more source

The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal

Cancers, 2022
The treatment of locally advanced rectal cancer (LARC) has evolved during the last decades, but recurrence remains a problem. Circulating tumor DNA (ctDNA) may result in an individualized treatment approach with improved survival and quality of life, but diverging results impede further development.
Edina Dizdarevic, Torben Hansen, Anders Jakobsen   +2 more
openaire   +3 more sources

Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC

Molecular Oncology, 2023
Brain metastasis (BM) genetically diverges from the primary tumor in non‐small‐cell lung cancer (NSCLC). Hence, accurately capturing clinically relevant alterations is pivotal for the delivery of targeted therapies.
Jun Wu, Zhiqiang Liu, Tianxiang Huang, Ying Wang, Meng Meng Song, Tao Song, Gretchen Long, Xiaobing Zhang, Xi Li, Longbo Zhang   +9 more
doaj   +1 more source

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop. [PDF]

The implementation of circulating tumor DNA (ctDNA) in the diagnostic routine may enable non-invasive predictive biomarker testing and treatment optimization in patients who lack a suitable tumor specimen, have failed previous molecular analysis or are ...
Patton, SJ, Koch, C, Schuuring, E, Heitzer, E, Giacomini, P, Fairley, JA, Joosse, SA, ELBS ctDNA Workshop Group, Toledo, RA, Deans, ZC, Pantel, K, de Jager, VD   +11 more
core   +1 more source

Emerging ctDNA detection strategies in clinical cancer theranostics [PDF]

, 2023
Circulating tumor DNA (ctDNA) is naked DNA molecules shed from the tumor cells into the peripheral blood circulation. They contain tumor‐specific gene mutations and other valuable information.
Kexin Yi, Sergey K. Filippov, Hongbo Zhang, Wang, Xiaoju, Yi, Kexin, Filippov, Sergej, Xiaoju Wang, Zhang, Hongbo   +7 more
core   +1 more source

Metal nanostructure‐coupled label‐free localized surface plasmon resonance biosensors for rapid and sensitive disease diagnosis

BMEMat, EarlyView.
LSPR biosensing enables rapid, sensitive, and low‐sample‐volume detection of biomarkers, with broad applications in diagnosing cancer, infectious, and chronic diseases. Advances in nanostructure design, micro/nanofabrication, and microfluidic integration have expanded the potential of LSPR sensors in biomedical diagnostics.
Zhaoxin Geng, Yunfei Sha, Jiongyan Yang, Hongru Yang, Xiao Liang   +4 more
wiley   +1 more source

Application of liquid biopsy in lung cancer management

Indian Journal of Pathology and Microbiology
Current advances in the understanding of the lung cancer landscape have drastically changed the approach to treating a patient with lung carcinoma. The field has progressed from analyzing single gene to using advanced techniques like next-generation ...
Shraddhanjali Satapathy, Balamurugan Thirunavukkarasu, Deepali Jain   +2 more
doaj   +1 more source